Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients
M.R. Vignon(Institut National de la Recherche Agronomique), Jean Paul Fermand(Université Paris Cité), Alexandre Karras(Délégation Paris 5), Bertrand Knebelmann(Hôpital Necker-Enfants Malades), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Guy Touchard(Centre Hospitalier Universitaire de Poitiers), Vincent Javaugue(Université de Poitiers), Nelson Leung(WinnMed), Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), K. El-Karoui, Damien Roos‐Weil(Sorbonne Université), Bouchra Asli(Hôpital Saint-Louis), Frank Bridoux(Université de Poitiers), Mariam P. Alexander(University of Minnesota Rochester), Bertrand Arnulf(Université Paris Cité)
Cited by 66
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695